Endometrial Carcinoma
Therapeutic response
Precision oncology relationships for therapeutic response involving this cancer type.
| Type | Biomarker(s) | Cancer type | Therapy(ies) | |
|---|---|---|---|---|
| Sensitivity (+) | dMMR | Endometrial Carcinoma | Carboplatin, Dostarlimab, Paclitaxel | FDA |
| Sensitivity (+) | MSI-H | Endometrial Carcinoma | Carboplatin, Dostarlimab, Paclitaxel | FDA |
| Sensitivity (+) | dMMR | Endometrial Carcinoma | Dostarlimab | FDA |
| Sensitivity (+) | dMMR | Endometrial Carcinoma | Carboplatin, Durvalumab, Paclitaxel | FDA |
| Sensitivity (+) | MSI-L | Endometrial Carcinoma | Lenvatinib, Pembrolizumab | FDA |
| Sensitivity (+) | pMMR | Endometrial Carcinoma | Pembrolizumab | FDA |
| Sensitivity (+) | MSI-H | Endometrial Carcinoma | Pembrolizumab | FDA |
| Sensitivity (+) | dMMR | Endometrial Carcinoma | Carboplatin, Durvalumab, Paclitaxel | HC |
| Sensitivity (+) | dMMR | Endometrial Carcinoma | Dostarlimab | HC |
| Sensitivity (+) | MSI-H | Endometrial Carcinoma | Dostarlimab | HC |